Glucagon like peptide 1 (GLP1)-growth differentiation factor 15 (GDF15) fusion proteins and uses thereof

US12275770B2 · kind B2 · utility

Assignee

• Janssen Sciences Ireland Unlimited Company · IE

Inventors

• Shannon Mullican · Philadelphia, US
• Matthew M. RANKIN · Spring House, US
• Xiefan Lin-Schmidt · Ambler, US
• Chichi Huang · Malvern, US
• Jennifer Furman · Tucson, US
• Songmao Zheng · Spring House, US
• Shamina M. Rangwala · Furlong, US
• Serena Nelson · San Diego, US

Key dates

• Filing date: Jun 9, 2023
• Grant date: Apr 15, 2025
• Expiry date: Jun 9, 2043

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/31
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are method of using GLP1-GDF15 fusion proteins for reducing food intake, preventing, treating or ameliorating diseases and disorders, such as obesity, type 2 diabetes, the metabolic syndrome, insulin resistance, and dyslipidemia, among others, the fusion protein comprising a GLP1 or GLP1 variant peptide, a first linker peptide, a serum albumin protein, a second linker peptide, and a GDF15 protein.